RLYB Stock Overview
A clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rallybio Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.10 |
| 52 Week High | US$3.46 |
| 52 Week Low | US$0.95 |
| Beta | -1.67 |
| 11 Month Change | 5.77% |
| 3 Month Change | -7.56% |
| 1 Year Change | -43.88% |
| 33 Year Change | -90.71% |
| 5 Year Change | n/a |
| Change since IPO | -92.20% |
Recent News & Updates
Recent updates
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully
Aug 28
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?
Jan 04Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?
Sep 19Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
May 15We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth
Jan 30Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
Oct 31Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
Jul 07Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans
Mar 16Shareholder Returns
| RLYB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.7% | 4.3% | 1.6% |
| 1Y | -43.9% | 18.8% | 32.3% |
Return vs Industry: RLYB underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: RLYB underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| RLYB volatility | |
|---|---|
| RLYB Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RLYB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RLYB's weekly volatility has decreased from 17% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 25 | Steve Uden | www.rallybio.com |
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Rallybio Corporation Fundamentals Summary
| RLYB fundamental statistics | |
|---|---|
| Market cap | US$44.81m |
| Earnings (TTM) | -US$66.97m |
| Revenue (TTM) | US$598.00k |
76.3x
P/S Ratio-0.7x
P/E RatioIs RLYB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLYB income statement (TTM) | |
|---|---|
| Revenue | US$598.00k |
| Cost of Revenue | -US$5.50m |
| Gross Profit | US$6.10m |
| Other Expenses | US$73.07m |
| Earnings | -US$66.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 1,019.40% |
| Net Profit Margin | -11,199.50% |
| Debt/Equity Ratio | 0% |
How did RLYB perform over the long term?
See historical performance and comparison